<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196231</url>
  </required_header>
  <id_info>
    <org_study_id>BEYOND Protocol</org_study_id>
    <nct_id>NCT04196231</nct_id>
  </id_info>
  <brief_title>Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)</brief_title>
  <acronym>BEYOND</acronym>
  <official_title>Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      BEYOND represents an open-label, parallel, three-arm randomized controlled trial, aimed at
      evaluating the effects of combination therapy of fixed ratio basal insulin/GLP-1 receptor
      agonist (GLP-1RA) or basal insulin/SGLT-2 inhibitors (SGLT-2i) on the durability of the
      glycemic control, as compared with the basal bolus insulin regimen, in people with type 2
      diabetes failing to achieve glycemic targets with injective therapy. The potential benefits
      for participants in the study include the possibility of improving the glyco-metabolic
      control with drugs that have been evaluated as safe and protective for the heart and the
      kidneys.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hba1c variability change</measure>
    <time_frame>Baseline, 3 months, 6 months, 9 months, 12 months</time_frame>
    <description>Persistent 30% variability in HbA1c during the follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions of patients with significant HbA1c change</measure>
    <time_frame>Baseline, 3 months, 6 months, 9 months, 12 months</time_frame>
    <description>Proportions of patients undergoing a reduction equal or higher than 0.5% as compared with baseline levels during the follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Change</measure>
    <time_frame>Baseline, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI Change</measure>
    <time_frame>Baseline, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference change</measure>
    <time_frame>Baseline, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure change</measure>
    <time_frame>Baseline, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glycemia change</measure>
    <time_frame>Baseline, 3months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-prandial glycemia change</measure>
    <time_frame>Baseline, 3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide change</measure>
    <time_frame>Baseline, 1 week, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total daily insulin dose</measure>
    <time_frame>Baseline, 3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipide profile</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Difference between groups in total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes treatment satisfaction</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>In order to measure satisfaction with diabetes treatment regimens, we used the self-reported Diabetes Treatment Satisfaction Questionnaire. This instrument aims to assess levels of satisfaction in subjects using different treatment strategies. The questionnaire consists of eight questions: six questions addresses general satisfaction with a score from 0 to 6 for each question (0 = worst), that has to be computed in a total score ranging from 0 (=worst) to 36 (=best); among the remaining two questions, which has to be computed separately as two subscales, one concerns the perception of hyperglycemic events and another the perception of hypoglycemic events, both with a score from 0 (none of the time) to 6 (most of the time).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>FR insulin/GLP-1RA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin/SGLT-2i</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal Bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDegLira</intervention_name>
    <description>IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose &gt;130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose &lt; 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).</description>
    <arm_group_label>FR insulin/GLP-1RA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGlarLixi</intervention_name>
    <description>IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose &gt;130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose &lt; 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).</description>
    <arm_group_label>FR insulin/GLP-1RA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin/Canaglifozin</intervention_name>
    <description>Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose &gt;130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose &lt; 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c &gt;7.5 after 12 weeks).</description>
    <arm_group_label>Insulin/SGLT-2i</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin/Dapaglifozin</intervention_name>
    <description>Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose &gt;130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose &lt; 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration</description>
    <arm_group_label>Insulin/SGLT-2i</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin/Empaglifozin</intervention_name>
    <description>Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose &gt;130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose &lt; 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c &gt;7.5 after 12 weeks).</description>
    <arm_group_label>Insulin/SGLT-2i</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basal Bolus</intervention_name>
    <description>Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose &gt;130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose &lt; 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.</description>
    <arm_group_label>Basal Bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Poor glycemic control (HbA1c ≥7.5%)

          -  Stable basal bolus insulin regimen for almost a year, eventually associated with
             metformin.

        Exclusion Criteria:

          -  Type 1 diabetes or secondary diabetes;

          -  Previous treatment for the last three months with GLP-1RA or DPP-4 inhibitors;

          -  Hypersensitivity towards active substances or other ingredients of the drugs used in
             the study

          -  Participation in other trial with experimental drugs within 30 days

          -  Diseases that represent contraindication to GLP-1RA use (pancreatitis, gallstones)

          -  Pregnancy or planned pregnancy within the time of the study

          -  Serum creatinine &gt; 1,3 mg/dL in women and &gt;1,4 mg/dL in men

          -  eGFR &lt; 30 mL/min

          -  Previous cancer or antineoplastic therapy for five years before randomization

          -  Current therapy with glucocorticoid (oral, topic or sistemic administration) or with
             antypsichotic drugs

          -  Previous ketoacidosis

          -  Any clinical, psychologic or psychiatric condition that is incompatible with the study
             according to the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Esposito, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit of Diabetology University of Campania Luigi Vanvitelli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dario Giugliano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit of Endocrinology and Metabolic Diseases University of Campania Luigi Vanvitelli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Bellastella, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Endocrinology and Metabolic Diseases University of Campania Luigi Vanvitelli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Ida Maiorino, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Diabetology University of Campania Luigi Vanvitelli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Esposito, MD, PhD</last_name>
    <phone>+39 0815665031</phone>
    <email>katherine.esposito@unicampania.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unit of Endocrinology and Metabolic Diseases</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dario Giugliano, Principal Investigator</last_name>
      <phone>+39 0815665054</phone>
      <email>dario.giugliano@unicampania.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Giugliano D, Bellastella G, Maiorino MI, Esposito K. Beyond basal-bolus insulin regimen: Is it still the ultimate chance for therapy in diabetes? Diabetes Res Clin Pract. 2019 Nov;157:107922. doi: 10.1016/j.diabres.2019.107922. Epub 2019 Nov 9.</citation>
    <PMID>31715201</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Katherine Esposito</investigator_full_name>
    <investigator_title>Full Professor of Endocrinology and Metabolic Diseases</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>GLP-1RA</keyword>
  <keyword>SGLT-2i</keyword>
  <keyword>basal insulin</keyword>
  <keyword>basal bolus</keyword>
  <keyword>glycemic control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

